PMC:7115396 / 6978-7240 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T86","span":{"begin":17,"end":19},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T87","span":{"begin":106,"end":108},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T88","span":{"begin":114,"end":119},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T89","span":{"begin":251,"end":258},"obj":"http://purl.obolibrary.org/obo/CLO_0001409"}],"text":"tive antibodies [34]. Therefore, some researchers have created an attenuated IBV vaccine by replacing the S1 or S genes from other virulent strains using reverse genetic technology to generate protection against strains of the corresponding serotype [5], [28], ["}

{"project":"2_test","denotations":[{"id":"32057575-7980002-143294057","span":{"begin":17,"end":19},"obj":"7980002"},{"id":"32057575-12885925-143294058","span":{"begin":251,"end":252},"obj":"12885925"}],"text":"tive antibodies [34]. Therefore, some researchers have created an attenuated IBV vaccine by replacing the S1 or S genes from other virulent strains using reverse genetic technology to generate protection against strains of the corresponding serotype [5], [28], ["}

{"project":"LitCovid-PubTator","denotations":[{"id":"103","span":{"begin":77,"end":80},"obj":"Species"}],"attributes":[{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"Tax:11120"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"tive antibodies [34]. Therefore, some researchers have created an attenuated IBV vaccine by replacing the S1 or S genes from other virulent strains using reverse genetic technology to generate protection against strains of the corresponding serotype [5], [28], ["}